Targeting the p53 Pathway in Ewing Sarcoma

Table 3

MDM2 amplification or CDKN2A deletion in Ewing Sarcomas.

Study	MDM2 amplification	Study	CDKN2A deletion
Kovar et al., 1993 [5]	0/17	Kovar et al., 1997 [5]	7/27^#
Ladanyi et al., 1995 [58]	3/30	Wei et al., 2000 [59]	7/39^#
Tsuchiya et al., 2000 [10]	0/24	López-Guerrero et al., 2001 [11]	4/19^#
Park et al., 2001 [13]	0/35	Brownhill et al., 2007 [60]	6/42*
López-Guerrero et al., 2001 [11]	0/19	López-Guerrero et al., 2010 [48]	34/169*
Total MDM Amplifications	3/125 (2.4%)	Total CDKN2A Deletions	58/296 (19.6%)

#Homozygous deletion of CDKN2A
∗Includes both homozygous and hemizygous deletions of CDKN2A.